MPT Product Development Database

Multipurpose Prevention Technologies (MPTs) are an innovative class of products that deliver varied combinations of HIV prevention, other STI prevention, and contraception and will improve the lives of women and families worldwide.

This database includes MPT products that are currently funded and in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.

Click on the tables for MPT products in the development pipeline, listed by:
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Hormonal/Non-HormonalDelivery RouteDelivery MethodDevelopment Stage
IndicationProduct DeveloperProduct Sponsor/FundingActive Ingredient
Key Word Search   

25 product(s) found

TAF / Elvitegravir Topical Insert

MPT in Development

Development Stage:
Clinical – Phase 1 Trial (C1)
Delivery Route & Method:
Topical - Fast Dissolving Insert – Vaginal, Rectal
Mechanism of Action:
Nucleoside analogue reverse transcriptase inhibitor (NRTI); Integrase strand-transfer inhibitor
  • Funding:
  • National Institutes of Health (NIH)
  • U.S. Agency for International Development (USAID)
  • Funding Mechanism:
    NIH: Microbicide Trials Network (MTN)
    USAID: Cooperative Agreement, Interagency Agreement [USAID-CDC]
    Past Funding:
    Bill & Melinda Gates Foundation
    Active Ingredient:
  • Elvitegravir
  • Tenofovir Alafenamide (TAF)
  • Product Indications:
  • HIV
  • HSV-2
  • Description:
    Solid, tablet-like dosage form for dual-compartment (vaginal or rectal) on-demand use. Studies in non-human primates demonstrate proof-of-concept that a single TAF/EVG insert dosed vaginally several hours either before or after SHIV exposure provides strong protection. A Phase I study to assess safety, pharmacokinetics, and pharmacodynamics of the TAF/EVG insert administered vaginally (CONRAD A18-146) was completed in early 2019; dissemination of results is planned mid-2020. A Phase 1 study to assess rectal administration of the TAF/EVG insert (MTN-039) was initiated in late 2019 and is ongoing. A placebo form of this insert was also evaluated in two international, multi-site acceptability studies, including the Quatro study, comparing four vaginal dosage forms in African women, and the MTN-035 (DESIRE) study, comparing three different rectal dosage forms.
    IMPT Secretariat
    1750 Howe Avenue, Suite 550
    Sacramento, CA 95825

    The Initiative for Multipurpose Prevention Technologies (IMPT) is a project of CAMI Health, a social impact organization dedicated to improving the health of women and their families worldwide. CAMI Health is housed at the Public Health Institute (PHI).

    © Copyright 2020, Public Health Institute / CAMI Health / IMPT Secretariat. All rights reserved.